Merck (MRK) Deferred Taxes (2009 - 2026)

Merck (MRK) has reported Deferred Taxes for 18 consecutive years, with -$544.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Deferred Taxes fell 21.43% year-over-year to -$544.0 million in Q2 2026; TTM through Jun 2026 was -$1.9 billion, a 14.84% decrease from a year earlier, with the FY2025 full-year figure at -$1.7 billion, down 33.79% from the prior year.
• Deferred Taxes was -$544.0 million for Q2 2026 at Merck, down from -$315.0 million in the prior quarter.
• Over five years, Deferred Taxes peaked at -$51.0 million in Q1 2024 and troughed at -$931.0 million in Q4 2023.
• A 5-year average of -$402.6 million and a median of -$337.0 million in 2022 frame the typical range for Deferred Taxes.
• Across the five-year window, Deferred Taxes slumped 66000.0% in 2022 and surged 81.59% in 2024, its largest moves.
• Over 5 years, Deferred Taxes stood at -$307.0 million in 2022, then tumbled by 203.26% to -$931.0 million in 2023, then surged by 33.83% to -$616.0 million in 2024, then sank by 33.93% to -$825.0 million in 2025, then jumped by 34.06% to -$544.0 million in 2026.
• The last three Deferred Taxes figures came in at -$544.0 million (Q2 2026), -$315.0 million (Q1 2026), and -$825.0 million (Q4 2025), per Business Quant data.